Home > Search Results: Muñoz-Couselo, Eva
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 6 records in 0.02 seconds.
Articles, 5 records found
Research literature, 1 records found
Articles 5 records found  
1.
12 p, 940.4 KB An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury / Riveiro Barciela, Mar (Universitat Autònoma de Barcelona. Departament de Medicina) ; Barreira-Diaz, Ana (Hospital Universitari Vall d'Hebron) ; Salcedo, Maria-Teresa (Hospital Universitari Vall d'Hebron) ; Callejo, Ana (Hospital Universitari Vall d'Hebron) ; Muñoz Couselo, Eva (Hospital Universitari Vall d'Hebron) ; Iranzo, Patricia (Hospital Universitari Vall d'Hebron) ; Ortiz Velez, Carolina (Hospital Universitari Vall d'Hebron) ; Cedrés, Susana (Hospital Universitari Vall d'Hebron) ; Díaz Mejía, Nely (Hospital Universitari Vall d'Hebron) ; Ruiz Cobo, Juan Carlos (Hospital Universitari Vall d'Hebron) ; Morales, Rafael (Hospital Universitari Vall d'Hebron) ; Aguilar-Company, Juan (Hospital Universitari Vall d'Hebron) ; Zamora, Ester (Hospital Universitari Vall d'Hebron) ; Oliveira, Mafalda (Hospital Universitari Vall d'Hebron) ; Sanz-Martínez, María Teresa (Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Viladomiu, Lluis (Universitat Autònoma de Barcelona. Departament de Medicina) ; Martínez Gallo, Mónica (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Buti, Maria (Universitat Autònoma de Barcelona. Departament de Medicina)
Background: There are few data on corticosteroids (CS)-sparing strategies for checkpoint inhibitor (ICI)-induced liver injury (ChILI). Aim: We aimed to assess the performance of a 2-step algorithm for severe ChILI, based on ICI temporary discontinuation (step-1) and, if lack of biochemical improvement, CS based on the degree of necroinflammation at biopsy (step-2). [...]
2024 - 10.1111/apt.17898
Alimentary Pharmacology and Therapeutics, Vol. 59 Núm. 7 (april 2024) , p. 865-876  
Detailed record - Creative Commons
2.
14 p, 928.6 KB Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice / Sabaté, Mònica (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Pérez, Eulàlia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia Doladé, Núria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Vidal Guitart, Xavier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Carreras Soler, Maria Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Farriols Danés, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Braña, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Carles, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Morales-Barrera, Rafael (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Muñoz Couselo, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Data related to adverse drug reactions (ADRs), specifically immune-related adverse events (irAEs), in long-term treatment with immunotherapy in real-world practice is scarce, as is general information regarding the management of ADRs. [...]
2022 - 10.3389/fmed.2022.891179
Frontiers in Medicine, Vol. 9 (august 2022)  
Detailed record - Creative Commons
3.
10 p, 1.1 MB SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019) / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; García-Martínez, E. (Hospital General Universitario Morales Meseguer (Múrcia)) ; Martinez, M. (Hospital del Mar (Barcelona, Catalunya)) ; Muñoz Couselo, Eva (Vall d'Hebron Institut d'Oncologia) ; Rodriguez-Abreu, D. (C.H.U. Insular-Materno Infantil de Gran Canaria) ; Alvarez, R. (Hospital Virgen de la Salud (Toledo)) ; Arance, Ana (Hospital Clínic i Provincial de Barcelona) ; Berrocal, A. (Hospital General Universitario de Valencia) ; de la Cruz Merino, Luis (Universidad de Sevilla) ; Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ; Universitat Autònoma de Barcelona
The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. [...]
2020 - 10.1007/s12094-019-02273-x
Clinical & Translational Oncology, Vol. 22 Núm. 2 (january 2020) , p. 213-222  
Detailed record - Creative Commons
4.
14 p, 4.2 MB STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation / Granado-Martínez, Paula (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia-Ortega, Sara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; González-Sánchez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; McGrail, Kimberley (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Selgas, Rafael (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ; Gil, Rosa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Naldaiz-Gastesi, Neia (Present Address: Biodonostia, Neurosciences Area, Group of Neuromuscular Diseases) ; Rhodes, Ana C. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron) ; Ferrer, Berta (Hospital Universitari Vall d'Hebron) ; Canals, Francesc (Vall d'Hebron Institut d'Oncologia) ; Villanueva, Josep (Vall d'Hebron Institut d'Oncologia) ; Méndez Fernández, Olga (Vall d'Hebron Institut d'Oncologia) ; Espinosa-Gil, Sergio (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Lizcano de Vega, José Miguel (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Muñoz Couselo, Eva (Vall d'Hebron Institut d'Oncologia) ; García-Patos Briones, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Recio Conde, Juan Ángel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Elucidating the contribution of somatic mutations to cancer is essential for personalized medicine. STK11 (LKB1) appears to be inactivated in human cancer. However, somatic missense mutations also occur, and the role/s of these alterations to this disease remain unknown. [...]
2020 - 10.1038/s42003-020-1092-0
Communications Biology, Vol. 3 (july 2020)  
Detailed record - Creative Commons
5.
8 p, 215.1 KB Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer / Muñoz Couselo, Eva (Hospital Universitari Vall d'Hebron) ; Pérez-García, José (Hospital Universitari Vall d'Hebron) ; Cortés, Javier (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Metastatic breast cancer (MBC) remains an incurable disease, with the goals of care aimed at maximizing the patient's duration and quality of life. Treatment options for MBC have become more efficacious and numerous. [...]
2011 - 10.2147/OTT.S16392
OncoTargets and therapy, Vol. 4 (november 2011) , p. 185-192  
Detailed record - Creative Commons

Research literature 1 records found  
1.
184 p, 14.3 MB Evaluación inmunogénica de los tumores de mama triple negativos en relación a la presencia o no de linfocitos intratumorales / Quintana Vega, Ángela ; Cortés, Javier, dir. ; Muñoz Couselo, Eva, dir. ; Peg, Vicente, dir. ; Selva O'Callaghan, Albert, dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
El cáncer de mama triple negativo es el subtipo que actualmente tiene el peor pronóstico de todos los cánceres de mama. Son un 15% de todos ellos, suelen aparecer en pacientes jóvenes y su progresión es tan rápida que un 70% fallece en los cinco primeros años. [...]
El cáncer de mama triple negativo es el subtipo que actualmente tiene el peor pronóstico de todos los cánceres de mama. Son un 15% de todos ellos, suelen aparecer en pacientes jóvenes y su progresión es tan rápida que un 70% fallece en los cinco primeros años. [...]
Triple Negative Breast Cancer is the tumor subtype that currently has the worst prognosis of all breast malignancies. This subtype represents 15% of all breast cancer, commonly appearing in young women, and progressing so rapidly that 70% of patients succumb within 5 years of diagnosis. [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2019.  
Detailed record - Creative Commons

See also: similar author names
1 Muñoz-Couselo, E.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with